Mixed Data For Bluebird's LentiGlobin, But Conditional Approval On The Cards
Over the last week bluebird bio has reported first interim Phase III data from the Northstar-2 trial of blood disease drug LentiGlobin and announced a public offering of $350m of common stock.
You may also be interested in...
Company highlights LentiGlobin sickle cell and beta thalassemia data updates in investor call about the upcoming ASH meeting, which will feature 11 presentations across its clinical and preclinical programs.
Manufacturing, distribution and pricing challenges for cell and gene therapies have been mostly hypothetical – until now. But with no industry standards, the first products to win approval are dictating the complex path forward.
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.